Publications
Search our bibliography using the filters on the right-hand side.
Displaying 1 through 6 of 6 publications.
Skip to main content
Krege JH, Gilsenan AW, Komacko JL, Kellier-Steele N. Teriparatide and osteosarcoma risk: history, science, elimination of boxed warning, and other label updates. J Bone Miner Res. 2022 Aug 14;6(9):e10665. doi: 10.1002/jbm4.10665
Kruse-Jarres R, Gilsenan AW, Spears J, Kaye JA. Prospective, observational study of plasma-derived factor VIII/von Willebrand factor in immune tolerance induction: the PRISM registry. Haemophilia. 2015 Mar;21(2):e122-4. doi: 10.1111/hae.12590
Kellier N, Krohn K, Gilsenan AW, Harris DH, Andrews EB, Massica D. Forteo voluntary patient registry: 3-Year progress on a prospective osteosarcoma surveillance study. Poster presented at the American Society for Bone and Mineral Research Annual Meeting; October 6, 2013.
Gilsenan AW, Kellier N, Harris DH, Andrews EB, Masica DN. Linking a voluntary patient registry with US state cancer registries for possible signal detection. Poster presented at the 28th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 23, 2012. Barcelona, Spain. [abstract] Pharmacoepidemiol Drug Saf. 2012 Aug 27; 21(suppl 3):464. doi: 10.1002/pds.3324
Gilsenan AW, Wang J, Midkiff KD, Andrews EB. Assessing the impact of potential selection bias on prevalence estimates of lower urinary tract symptoms in a primary care setting. Poster presented at the 23rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management; 2007.
Gilsenan A, Zhou X, Coste F, Allshouse AA. Comparison of data from a US national survey (NHANES) with data from a cohort recruited from the internet. Poster presented at the 22nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2006. Lisbon, Portugal.